Biohaven (BHVN) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Biohaven (BHVN) over the past year, gaining 75.5% versus a loss of 22.2%. Palvella Therapeutics is the larger company by market cap ($2.00 billion vs $1.85 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | PVLA |
|---|---|---|
| Share price | $12.26 | $139.15 |
| Market cap | $1.85B | $2.00B |
| 1-day change | +2.77% | +5.95% |
| YTD return | +5.67% | +25.48% |
| 1-year return | -22.23% | +75.47% |
| 5-year return | — | -63.60% |
| EPS (TTM) | $-4.56 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-738.82M | $-41.72M |
| 52-week high | $18.57 | $161.38 |
| 52-week low | $7.48 | $65.93 |
| Distance from 52-week high | -33.97% | -13.77% |
| Analyst consensus | buy | none |
| Avg. price target upside | +73.49% | +65.67% |
| Average volume | 2.62M | 211.36K |
| Shares outstanding | 151.04M | 14.41M |
| Employees | 274 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed BHVN by 97.7 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
BHVN vs PVLA FAQ
Which is bigger, Biohaven or Palvella Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $2.00B compared with $1.85B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or PVLA?
PVLA returned +75.47% over the past 12 months, compared with -22.23% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.